About PopVax
PopVax is a company based in Hyderabad (India) founded in 2021 by Soham Sankaran. The company has 49 employees as of March 31, 2024. PopVax offers products and services including mRNA Vaccines, LNP Delivery Platform, and Therapeutics Platform. PopVax operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Hyderabad, India
- Employees 49 as on 31 Mar, 2024
- Founders Soham Sankaran
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Popvax Private Limited
- Date of Incorporation 26 Jul, 2021
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$4.02 M (USD)2585.98as on Mar 31, 2023
-
Net Profit
$384.66 K (USD)5717.4as on Mar 31, 2023
-
EBITDA
$846.81 K (USD)7655.99as on Mar 31, 2023
-
Latest Funding Round
$3.6 M (USD), Grant
Sep 01, 2025
-
Investors
BARDA
& 1 more
-
Employee Count
49
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PopVax
PopVax offers a comprehensive portfolio of products and services, including mRNA Vaccines, LNP Delivery Platform, and Therapeutics Platform.
Designs vaccines for COVID-19 and other pathogens using computational methods.
Provides mRNA delivery with novel ionizable lipids for therapeutic applications.
Develops treatments for chronic infections and diseases via protein design.
People of PopVax
Unlock access to complete
Funding Insights of PopVax
Investors in PopVax
PopVax has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include BARDA and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BARDA is focused on developing medical countermeasures for public health security.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for PopVax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PopVax
Investment portfolio details for PopVax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PopVax
Detailed financials for PopVax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Popvax Comparisons
Peer comparison for PopVax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PopVax
PopVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of PopVax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Popvax
Complete news archive for PopVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PopVax
PopVax was founded in 2021 and raised its 1st funding round 4 years after it was founded.
PopVax is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
As of Mar 31, 2024, the latest employee count at PopVax is 49.
Annual revenue of PopVax is $4.02M as on Mar 31, 2023.
Developer of mRNA platform for vaccines and therapeutics. It offers multivariant thermostable vaccine for SARS-CoV-2 treatment.
PopVax's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
PopVax offers mRNA Vaccines, LNP Delivery Platform, and Therapeutics Platform.
PopVax has 2 investors. Key investors include BARDA, and Gates Foundation.